A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo
Open accessThe DOI matches its Crossref record.
Abstract
The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors. We have previously shown that tumor cells can be targeted by EphA2 monoclonal antibodies and that these antibodies function, in part, by inducing EphA2 internalization and degradation. In this report, we describe the isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds both the human and rodent EphA2 receptor. After cell binding, the antibody induces rapid tyrosine phosphorylation, internalization, and degradation of the EphA2 receptor. Because monoclonal antibodies that selectively bind tumor cells and internalize provide a vehicle for targeted delivery of cytotoxics, 1C1 was conjugated to the microtubule inhibitor monomethylauristatin phenylalanine using a stable maleimidocaproyl linker. The anti-EphA2 antibody-drug conjugate [1C1–maleimidocaproyl-MMAF (mcMMAF)] stimulated the activation of caspase-3/caspase-7 and the death of EphA2-expressing cells with IC50 values as low as 3 ng/mL. Similarly, the conjugate induced degradation of the EphA2 receptor and inhibited tumor growth in vivo. Administration of 1C1-mcMMAF at doses as low as 1 mg/kg once weekly resulted in significant growth inhibition of EphA2-expressing tumors without any observable adverse effects in mouse xenograft and rat syngeneic tumor models. Our data support the use of an antibody-drug conjugate approach to selectively target and inhibit the growth of EphA2-expressing tumors. [Cancer Res 2008;68(22):9367–74]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 44
- Gale NW, Holland SJ, Valenzuela DM, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996; 17: 9–19. · DOI · Paper page
- Aoto J, Chen L. Bidirectional ephrin/Eph signaling in synaptic functions. Brain Res 2007; 1184: 72–80. · DOI
- Orioli D, Klein R. The eph receptor family: axonal guidance by contact repulsion. Trends Genet 1997; 13: 354–9. · DOI · Paper page
- Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by eph-ephrin interactions. Trends Cardiovasc Med 2007; 17: 145–51. · DOI · Paper page
- Brantley-Sieders DM, Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 2004; 7: 17–28. · DOI
- Zhang J, Hughes S. Role of the ephrin and eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 2006; 208: 453–61. · DOI
- Surawska H, Ma PC, Salgia R. The role of Ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419–33. · DOI · Paper page
- Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005; 5: 149–57. · DOI · Paper page
- Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005; 3: 541–51. · DOI · Paper page
- Meade-Tollin L, Martinez JD. Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients. Cancer Biol Ther 2007; 6: 288–9. · DOI
- Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003; 103: 657–63. · DOI · Paper page
- Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005; 11: 226–31. · DOI
- Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301–6.
- Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76: 1–20. · DOI · Paper page
- Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000; 2: 62–9. · DOI · Paper page
- Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8: 111–8. · DOI · Paper page
- Coffman KT, Hu M, Carles-Kinch K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 2003; 63: 7907–12.
- Landen CN, Jr., Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006; 98: 1558–70. · DOI
- Brantley DM, Cheng N, Thompson EJ, et al. Soluble eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011–26. · DOI · Paper page
- Cheng N, Brantley D, Fang WB, et al. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003; 5: 445–56. · DOI
- Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 2007; 6: 3208–18. · DOI
- Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118–29. · DOI · Paper page
- Kiewlich D, Zhang J, Gross C, et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 2006; 8: 18–30. · DOI
- Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778–84. · DOI · Paper page
- Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2007; 110: 616–23. · DOI · Paper page
- Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006; 66: 2328–37. · DOI
- Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17: 114–24. · DOI · Paper page
- Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 2005; 23: 344–8. · DOI · Paper page
- Jostock T, Vanhove M, Brepoels E, et al. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 2004; 289: 65–80. · DOI
- Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002; 62: 2840–7.
- Bai R, Roach MC, Jayaram SK, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993; 45: 1503–15. · DOI
- Cai W, Ebrahimnejad A, Chen K, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007; 34: 2024–36. · DOI
- Mirsalis JC, Schindler-Horvat J, Hill JR, et al. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 1999; 44: 395–402. · DOI
- Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 1990; 10: 6316–24. · doi:10.1128/mcb.10.12.6316-6324.1990 · Paper page
- Hafner C, Schmitz G, Meyer S, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004; 50: 490–9. · DOI · Paper page
- Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001; 7: 3640–8.
- Ogawa K, Pasqualini R, Lindberg RA, et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 6043–52. · DOI · Paper page
- Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science 1995; 268: 567–9. · DOI · Paper page
- Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 2007; 7: 566–81. · DOI
- Mao W, Luis E, Ross S, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 2004; 64: 781–8. · DOI · Paper page
- Brantley-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008; 118: 64–78. · DOI · Paper page
- Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2001; 2: 313–25. · doi:10.2174/1389201013378635
- Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58: 640–56. · DOI · Paper page
- Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137–46. Review. · DOI · Paper page
Cited by
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Self-citationTherapeutic targeting of EPH receptors and their ligands
Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 341
Eph Receptors and Ephrins: Therapeutic Opportunities
Barquilla, A., & Pasquale, E. B. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140226 · Cited by 294
Metadata
- Authors
- Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P. D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P. A., & Tice, D. A.
- Venue
- Cancer Research
- Published
- 2008-11-14
- Volume
- 68
- Issue
- 22
- Pages
- 9367-9374
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2000027123
- Cited by
- 150
- References
- 0
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-1933
- The paper
- Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P. D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P. A., & Tice, D. A. (2008). A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-1933
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.